Tag Archives: direct

#437912 “Boston Dynamics Will Continue to ...

Last week’s announcement that Hyundai acquired Boston Dynamics from SoftBank left us with a lot of questions. We attempted to answer many of those questions ourselves, which is typically bad practice, but sometimes it’s the only option when news like that breaks.

Fortunately, yesterday we were able to speak with Michael Patrick Perry, vice president of business development at Boston Dynamics, who candidly answered our questions about Boston Dynamics’ new relationship with Hyundai and what the near future has in store.

IEEE Spectrum: Boston Dynamics is worth 1.1 billion dollars! Can you put that valuation into context for us?

Michael Patrick Perry: Since 2018, we’ve shifted to becoming a commercial organization. And that’s included a number of things, like taking our existing technology and bringing it to market for the first time. We’ve gone from zero to 400 Spot robots deployed, building out an ecosystem of software developers, sensor providers, and integrators. With that scale of deployment and looking at the pipeline of opportunities that we have lined up over the next year, I think people have started to believe that this isn’t just a one-off novelty—that there’s actual value that Spot is able to create. Secondly, with some of our efforts in the logistics market, we’re getting really strong signals both with our Pick product and also with some early discussions around Handle’s deployment in warehouses, which we think are going to be transformational for that industry.

So, the thing that’s really exciting is that two years ago, we were talking about this vision, and people said, “Wow, that sounds really cool, let’s see how you do.” And now we have the validation from the market saying both that this is actually useful, and that we’re able to execute. And that’s where I think we’re starting to see belief in the long-term viability of Boston Dynamics, not just as a cutting-edge research shop, but also as a business.

Photo: Boston Dynamics

Boston Dynamics says it has deployed 400 Spot robots, building out an “ecosystem of software developers, sensor providers, and integrators.”

How would you describe Hyundai’s overall vision for the future of robotics, and how do they want Boston Dynamics to fit into that vision?

In the immediate term, Hyundai’s focus is to continue our existing trajectories, with Spot, Handle, and Atlas. They believe in the work that we’ve done so far, and we think that combining with a partner that understands many of the industries in which we’re targeting, whether its manufacturing, construction, or logistics, can help us improve our products. And obviously as we start thinking about producing these robots at scale, Hyundai’s expertise in manufacturing is going to be really helpful for us.

Looking down the line, both Boston Dynamics and Hyundai believe in the value of smart mobility, and they’ve made a number of plays in that space. Whether it’s urban air mobility or autonomous driving, they’ve been really thinking about connecting the digital and the physical world through moving systems, whether that’s a car, a vertical takeoff and landing multi-rotor vehicle, or a robot. We are well positioned to take on robotics side of that while also connecting to some of these other autonomous services.

Can you tell us anything about the kind of robotics that the Hyundai Motor Group has going on right now?

So they’re working on a lot of really interesting stuff—exactly how that connects, you know, it’s early days, and we don’t have anything explicitly to share. But they’ve got a smart and talented robotics team that’s working in a variety of directions that shares overlap with us. Obviously, a lot of things related to autonomous driving shares some DNA with the work that we’re doing in autonomy for Spot and Handle, so it’s pretty exciting to see.

What are you most excited about here? How do you think this deal will benefit Boston Dynamics?

I think there are a number of things. One is that they have an expertise in hardware, in a way that’s unique. They understand and appreciate the complexity of creating large complex robotic systems. So I think there’s some shared understanding of what it takes to create a great hardware product. And then also they have the resources to help us actually build those products with them together—they have manufacturing resources and things like that.

“Robotics isn’t a short term game. We’ve scaled pretty rapidly but if you start looking at what the full potential of a company like Boston Dynamics is, it’s going to take years to realize, and I think Hyundai is committed to that long-term vision”

Another thing that’s exciting is that Hyundai has some pretty visionary bets for autonomous driving and unmanned aerial systems, and all of that fits very neatly into the connected vision of robotics that we were talking about before. Robotics isn’t a short term game. We’ve scaled pretty rapidly for a robotics company in terms of the scale of robots we’ve able to deploy in the field, but if you start looking at what the full potential of a company like Boston Dynamics is, it’s going to take years to realize, and I think Hyundai is committed to that long-term vision.

And when you’ve been talking with Hyundai, what are they most excited about?

I think they’re really excited about our existing products and our technology. Looking at some of the things that Spot, Pick, and Handle are able to do now, there are applications that many of Hyundai’s customers could benefit from in terms of mobility, remote sensing, and material handling. Looking down the line, Hyundai is also very interested in smart city technology, and mobile robotics is going to be a core piece of that.

We tend to focus on Spot and Handle and Atlas in terms of platform capabilities, but can you talk a bit about some of the component-level technology that’s unique to Boston Dynamics, and that could be of interest to Hyundai?

Creating very power-dense actuator design is something that we’ve been successful at for several years, starting back with BigDog and LS3. And Handle has some hydraulic actuators and valves that are pretty unique in terms of their design and capability. Fundamentally, we have a systems engineering approach that brings together both hardware and software internally. You’ll often see different groups that specialize in something, like great mechanical or electrical engineering groups, or great controls teams, but what I think makes Boston Dynamics so special is that we’re able to put everything on the table at once to create a system that’s incredibly capable. And that’s why with something like Spot, we’re able to produce it at scale, while also making it flexible enough for all the different applications that the robot is being used for right now.

It’s hard to talk specifics right now, but there are obviously other disciplines within mechanical engineering or electrical engineering or controls for robots or autonomous systems where some of our technology could be applied.

Photo: Boston Dynamics

Boston Dynamics is in the process of commercializing Handle, iterating on its design and planning to get box-moving robots on-site with customers in the next year or two.

While Boston Dynamics was part of Google, and then SoftBank, it seems like there’s been an effort to maintain independence. Is it going to be different with Hyundai? Will there be more direct integration or collaboration?

Obviously it’s early days, but right now, we have support to continue executing against all the plans that we have. That includes all the commercialization of Spot, as well as things for Atlas, which is really going to be pushing the capability of our team to expand into new areas. That’s going to be our immediate focus, and we don’t see anything that’s going to pull us away from that core focus in the near term.

As it stands right now, Boston Dynamics will continue to be Boston Dynamics under this new ownership.

How much of what you do at Boston Dynamics right now would you characterize as fundamental robotics research, and how much is commercialization? And how do you see that changing over the next couple of years?

We have been expanding our commercial team, but we certainly keep a lot of the core capabilities of fundamental robotics research. Some of it is very visible, like the new behavior development for Atlas where we’re pushing the limits of perception and path planning. But a lot of the stuff that we’re working on is a little bit under the hood, things that are less obvious—terrain handling, intervention handling, how to make safe faults, for example. Initially when Spot started slipping on things, it would flail around trying to get back up. We’ve had to figure out the right balance between the robot struggling to stand, and when it should decide to just lock its limbs and fall over because it’s safer to do that.

I’d say the other big thrust for us is manipulation. Our gripper for Spot is coming out early next year, and that’s going to unlock a new set of capabilities for us. We have years and years of locomotion experience, but the ability to manipulate is a space that’s still relatively new to us. So we’ve been ramping up a lot of work over the last several years trying to get to an early but still valuable iteration of the technology, and we’ll continue pushing on that as we start learning what’s most useful to our customers.

“I’d say the other big thrust for us is manipulation. Our gripper for Spot is coming out early next year, and that’s going to unlock a new set of capabilities for us. We have years and years of locomotion experience, but the ability to manipulate is a space that’s still relatively new to us”

Looking back, Spot as a commercial robot has a history that goes back to robots like LS3 and BigDog, which were very ambitious projects funded by agencies like DARPA without much in the way of commercial expectations. Do you think these very early stage, very expensive, very technical projects are still things that Boston Dynamics can take on?

Yes—I would point to a lot of the things we do with Atlas as an example of that. While we don’t have immediate plans to commercialize Atlas, we can point to technologies that come out of Atlas that have enabled some of our commercial efforts over time. There’s not necessarily a clear roadmap of how every piece of Atlas research is going to feed over into a commercial product; it’s more like, this is a really hard fundamental robotics challenge, so let’s tackle it and learn things that we can then benefit from across the company.

And fundamentally, our team loves doing cool stuff with robots, and you’ll continue seeing that in the months to come.

Photo: Boston Dynamics

Spot’s arm with gripper is coming out early next year, and Boston Dynamics says that’s going to “unlock a new set of capabilities for us.”

What would it take to commercialize Atlas? And are you getting closer with Handle?

We’re in the process of commercializing Handle. We’re at a relatively early stage, but we have a plan to get the first versions for box moving on-site with customers in the next year or two. Last year, we did some on-site deployments as proof-of-concept trials, and using the feedback from that, we did a new design pass on the robot, and we’re looking at increasing our manufacturing capability. That’s all in progress.

For Atlas, it’s like the Formula 1 of robots—you’re not going to take a Formula 1 car and try to make it less capable so that you can drive it on the road. We’re still trying to see what are some applications that would necessitate an energy and computationally intensive humanoid robot as opposed to something that’s more inherently stable. Trying to understand that application space is something that we’re interested in, and then down the line, we could look at creating new morphologies to help address specific applications. In many ways, Handle is the first version of that, where we said, “Atlas is good at moving boxes but it’s very complicated and expensive, so let’s create a simpler and smaller design that can achieve some of the same things.”

The press release mentioned a mobile robot for warehouses that will be introduced next year—is that Handle?

Yes, that’s the work that we’re doing on Handle.

As we start thinking about a whole robotic solution for the warehouse, we have to look beyond a high power, low footprint, dynamic platform like Handle and also consider things that are a little less exciting on video. We need a vision system that can look at a messy stack of boxes and figure out how to pick them up, we need an interface between a robot and an order building system—things where people might question why Boston Dynamics is focusing on them because it doesn’t fit in with our crazy backflipping robots, but it’s really incumbent on us to create that full end-to-end solution.

Are you confident that under Hyundai’s ownership, Boston Dynamics will be able to continue taking the risks required to remain on the cutting edge of robotics?

I think we will continue to push the envelope of what robots are capable of, and I think in the near term, you’ll be able to see that realized in our products and the research that we’re pushing forward with. 2021 is going to be a great year for us. Continue reading

Posted in Human Robots

#437884 Hyundai Buys Boston Dynamics for Nearly ...

This morning just after 3 a.m. ET, Boston Dynamics sent out a media release confirming that Hyundai Motor Group has acquired a controlling interest in the company that values Boston Dynamics at US $1.1 billion:

Under the agreement, Hyundai Motor Group will hold an approximately 80 percent stake in Boston Dynamics and SoftBank, through one of its affiliates, will retain an approximately 20 percent stake in Boston Dynamics after the closing of the transaction.

The release is very long, but does have some interesting bits—we’ll go through them, and talk about what this might mean for both Boston Dynamics and Hyundai.

We’ve asked Boston Dynamics for comment, but they’ve been unusually quiet for the last few days (I wonder why!). So at this point just keep in mind that the only things we know for sure are the ones in the release. If (when?) we hear anything from either Boston Dynamics or Hyundai, we’ll update this post.

The first thing to be clear on is that the acquisition is split between Hyundai Motor Group’s affiliates, including Hyundai Motor, Hyundai Mobis, and Hyundai Glovis. Hyundai Motor makes cars, Hyundai Mobis makes car parts and seems to be doing some autonomous stuff as well, and Hyundai Glovis does logistics. There are many other groups that share the Hyundai name, but they’re separate entities, at least on paper. For example, there’s a Hyundai Robotics, but that’s part of Hyundai Heavy Industries, a different company than Hyundai Motor Group. But for this article, when we say “Hyundai,” we’re talking about Hyundai Motor Group.

What’s in it for Hyundai?
Let’s get into the press release, which is filled with press release-y terms like “synergies” and “working together”—you can view the whole thing here—but still has some parts that convey useful info.

By establishing a leading presence in the field of robotics, the acquisition will mark another major step for Hyundai Motor Group toward its strategic transformation into a Smart Mobility Solution Provider. To propel this transformation, Hyundai Motor Group has invested substantially in development of future technologies, including in fields such as autonomous driving technology, connectivity, eco-friendly vehicles, smart factories, advanced materials, artificial intelligence (AI), and robots.

If Hyundai wants to be a “Smart Mobility Solution Provider” with a focus on vehicles, it really seems like there’s a whole bunch of other ways they could have spent most of a billion dollars that would get them there quicker. Will Boston Dynamics’ expertise help them develop autonomous driving technology? Sure, I guess, but why not just buy an autonomous car startup instead? Boston Dynamics is more about “robots,” which happens to be dead last on the list above.

There was some speculation a couple of weeks ago that Hyundai was going to try and leverage Boston Dynamics to make a real version of this hybrid wheeled/legged concept car, so if that’s what Hyundai means by “Smart Mobility Solution Provider,” then I suppose the Boston Dynamics acquisition makes more sense. Still, I think that’s unlikely, because it’s just a concept car, after all.

In addition to “smart mobility,” which seems like a longer-term goal for Hyundai, the company also mentions other, more immediate benefits from the acquisition:

Advanced robotics offer opportunities for rapid growth with the potential to positively impact society in multiple ways. Boston Dynamics is the established leader in developing agile, mobile robots that have been successfully integrated into various business operations. The deal is also expected to allow Hyundai Motor Group and Boston Dynamics to leverage each other’s respective strengths in manufacturing, logistics, construction and automation.

“Successfully integrated” might be a little optimistic here. They’re talking about Spot, of course, but I think the best you could say at this point is that Spot is in the middle of some promising pilot projects. Whether it’ll be successfully integrated in the sense that it’ll have long-term commercial usefulness and value remains to be seen. I’m optimistic about this as well, but Spot is definitely not there yet.

What does probably hold a lot of value for Hyundai is getting Spot, Pick, and perhaps even Handle into that “manufacturing, logistics, construction” stuff. This is the bread and butter for robots right now, and Boston Dynamics has plenty of valuable technology to offer in those spaces.

Photo: Bob O’Connor

Boston Dynamics is selling Spot for $74,500, shipping included.

Betting on Spot and Pick
With Boston Dynamics founder Marc Raibert’s transition to Chairman of the company, the CEO position is now occupied by Robert Playter, the long-time VP of engineering and more recently COO at Boston Dynamics. Here’s his statement from the release:

“Boston Dynamics’ commercial business has grown rapidly as we’ve brought to market the first robot that can automate repetitive and dangerous tasks in workplaces designed for human-level mobility. We and Hyundai share a view of the transformational power of mobility and look forward to working together to accelerate our plans to enable the world with cutting edge automation, and to continue to solve the world’s hardest robotics challenges for our customers.”

Whether Spot is in fact “the first robot that can automate repetitive and dangerous tasks in workplaces designed for human-level mobility” on the market is perhaps something that could be argued against, although I won’t. Whether or not it was the first robot that can do these kinds of things, it’s definitely not the only robot that do these kinds of things, and going forward, it’s going to be increasingly challenging for Spot to maintain its uniqueness.

For a long time, Boston Dynamics totally owned the quadruped space. Now, they’re one company among many—ANYbotics and Unitree are just two examples of other quadrupeds that are being successfully commercialized. Spot is certainly very capable and easy to use, and we shouldn’t underestimate the effort required to create a robot as complex as Spot that can be commercially used and supported. But it’s not clear how long they’ll maintain that advantage, with much more affordable platforms coming out of Asia, and other companies offering some unique new capabilities.

Photo: Boston Dynamics

Boston Dynamics’ Handle is an all-electric robot featuring a leg-wheel hybrid mobility system, a manipulator arm with a vacuum gripper, and a counterbalancing tail.

Boston Dynamics’ picking system, which stemmed from their 2019 acquisition of Kinema Systems, faces the same kinds of challenges—it’s very good, but it’s not totally unique.

Boston Dynamics produces highly capable mobile robots with advanced mobility, dexterity and intelligence, enabling automation in difficult, dangerous, or unstructured environments. The company launched sales of its first commercial robot, Spot in June of 2020 and has since sold hundreds of robots in a variety of industries, such as power utilities, construction, manufacturing, oil and gas, and mining. Boston Dynamics plans to expand the Spot product line early next year with an enterprise version of the robot with greater levels of autonomy and remote inspection capabilities, and the release of a robotic arm, which will be a breakthrough in mobile manipulation.

Boston Dynamics is also entering the logistics automation market with the industry leading Pick, a computer vision-based depalletizing solution, and will introduce a mobile robot for warehouses in 2021.

Huh. We’ll be trying to figure out what “greater levels of autonomy” means, as well as whether the “mobile robot for warehouses” is Handle, or something more like an autonomous mobile robot (AMR) platform. I’d honestly be surprised if Handle was ready for work outside of Boston Dynamics next year, and it’s hard to imagine how Boston Dynamics could leverage their expertise into the AMR space with something that wouldn’t just seem… Dull, compared to what they usually do. I hope to be surprised, though!

A new deep-pocketed benefactor

Hyundai Motor Group’s decision to acquire Boston Dynamics is based on its growth potential and wide range of capabilities.

“Wide range of capabilities” we get, but that other phrase, “growth potential,” has a heck of a lot wrapped up in it. At the moment, Boston Dynamics is nowhere near profitable, as far as we know. SoftBank acquired Boston Dynamics in 2017 for between one hundred and two hundred million, and over the last three years they’ve poured hundreds of millions more into Boston Dynamics.

Hyundai’s 80 percent stake just means that they’ll need to take over the majority of that support, and perhaps even increase it if Boston Dynamics’ growth is one of their primary goals. Hyundai can’t have a reasonable expectation that Boston Dynamics will be profitable any time soon; they’re selling Spots now, but it’s an open question whether Spot will manage to find a scalable niche in which it’ll be useful in the sort of volume that will make it a sustainable commercial success. And even if it does become a success, it seems unlikely that Spot by itself will make a significant dent in Boston Dynamics’ burn rate anytime soon. Boston Dynamics will have more products of course, but it’s going to take a while, and Hyundai will need to support them in the interim.

Depending on whether Hyundai views Boston Dynamics as a company that does research or a company that makes robots that are useful and profitable, it may be difficult for Boston Dynamics to justify the cost to develop the
next Atlas, when the
current one still seems so far from commercialization

It’s become clear that to sustain itself, Boston Dynamics needs a benefactor with very deep pockets and a long time horizon. Initially, Boston Dynamics’ business model (or whatever you want to call it) was to do bespoke projects for defense-ish folks like DARPA, but from what we understand Boston Dynamics stopped that sort of work after Google acquired them back in 2013. From one perspective, that government funding did exactly what it was supposed to do, which was to fund the development of legged robots through low TRLs (technology readiness levels) to the point where they could start to explore commercialization.

The question now, though, is whether Hyundai is willing to let Boston Dynamics undertake the kinds of low-TRL, high-risk projects that led from BigDog to LS3 to Spot, and from PETMAN to DRC Atlas to the current Atlas. So will Hyundai be cool about the whole thing and be the sort of benefactor that’s willing to give Boston Dynamics the resources that they need to keep doing what they’re doing, without having to answer too many awkward questions about things like practicality and profitability? Hyundai can certainly afford to do this, but so could SoftBank, and Google—the question is whether Hyundai will want to, over the length of time that’s required for the development of the kind of ultra-sophisticated robotics hardware that Boston Dynamics specializes in.

To put it another way: Depending whether Hyundai’s perspective on Boston Dynamics is as a company that does research or a company that makes robots that are useful and profitable, it may be difficult for Boston Dynamics to justify the cost to develop the next Atlas, when the current one still seems so far from commercialization.

Google, SoftBank, now Hyundai

Boston Dynamics possesses multiple key technologies for high-performance robots equipped with perception, navigation, and intelligence.

Hyundai Motor Group’s AI and Human Robot Interaction (HRI) expertise is highly synergistic with Boston Dynamics’s 3D vision, manipulation, and bipedal/quadruped expertise.

As it turns out, Hyundai Motors does have its own robotics lab, called Hyundai Motors Robotics Lab. Their website is not all that great, but here’s a video from last year:

I’m not entirely clear on what Hyundai means when they use the word “synergistic” when they talk about their robotics lab and Boston Dynamics, but it’s a little bit concerning. Usually, when a big company buys a little company that specializes in something that the big company is interested in, the idea is that the little company, to some extent, will be absorbed into the big company to give them some expertise in that area. Historically, however, Boston Dynamics has been highly resistant to this, maintaining its post-acquisition independence and appearing to be very reluctant to do anything besides what it wants to do, at whatever pace it wants to do it, and as by itself as possible.

From what we understand, Boston Dynamics didn’t integrate particularly well with Google’s robotics push in 2013, and we haven’t seen much evidence that SoftBank’s experience was much different. The most direct benefit to SoftBank (or at least the most visible one) was the addition of a fleet of Spot robots to the SoftBank Hawks baseball team cheerleading squad, along with a single (that we know about) choreographed gymnastics routine from an Atlas robot that was only shown on video.

And honestly, if you were a big manufacturing company with a bunch of money and you wanted to build up your own robotics program quickly, you’d probably have much better luck picking up some smaller robotics companies who were a bit less individualistic and would probably be more amenable to integration and would cost way less than a billion dollars-ish. And if integration is ultimately Hyundai’s goal, we’ll be very sad, because it’ll likely signal the end of Boston Dynamics doing the unfettered crazy stuff that we’ve grown to love.

Photo: Bob O’Connor

Possibly the most agile humanoid robot ever built, Atlas can run, climb, jump over obstacles, and even get up after a fall.

Boston Dynamics contemplates its future

The release ends by saying that the transaction is “subject to regulatory approvals and other customary closing conditions” and “is expected to close by June of 2021.” Again, you can read the whole thing here.

My initial reaction is that, despite the “synergies” described by Hyundai, it’s certainly not immediately obvious why the company wants to own 80 percent of Boston Dynamics. I’d also like a better understanding of how they arrived at the $1.1 billion valuation. I’m not saying this because I don’t believe in what Boston Dynamics is doing or in the inherent value of the company, because I absolutely do, albeit perhaps in a slightly less tangible sense. But when you start tossing around numbers like these, a big pile of expectations inevitably comes along with them. I hope that Boston Dynamics is unique enough that the kinds of rules that normally apply to robotics companies (or companies in general) can be set aside, at least somewhat, but I also worry that what made Boston Dynamics great was the explicit funding for the kinds of radical ideas that eventually resulted in robots like Atlas and Spot.

Can Hyundai continue giving Boston Dynamics the support and freedom that they need to keep doing the kinds of things that have made them legendary? I certainly hope so. Continue reading

Posted in Human Robots

#437783 Ex-Googler’s Startup Comes Out of ...

Over the last 10 years, the PR2 has helped roboticists make an enormous amount of progress in mobile manipulation over a relatively short time. I mean, it’s been a decade already, but still—robots are hard, and giving a bunch of smart people access to a capable platform where they didn’t have to worry about hardware and could instead focus on doing interesting and useful things helped to establish a precedent for robotics research going forward.

Unfortunately, not everyone can afford an enormous US $400,000 robot, and even if they could, PR2s are getting very close to the end of their lives. There are other mobile manipulators out there taking the place of the PR2, but so far, size and cost have largely restricted them to research labs. Lots of good research is being done, but it’s getting to the point where folks want to take the next step: making mobile manipulators real-world useful.

Today, a company called Hello Robot is announcing a new mobile manipulator called the Stretch RE1. With offices in the San Francisco Bay Area and in Atlanta, Ga., Hello Robot is led by Aaron Edsinger and Charlie Kemp, and by combining decades of experience in industry and academia they’ve managed to come up with a robot that’s small, lightweight, capable, and affordable, all at the same time. For now, it’s a research platform, but eventually, its creators hope that it will be able to come into our homes and take care of us when we need it to.

A fresh look at mobile manipulators
To understand the concept behind Stretch, it’s worth taking a brief look back at what Edsinger and Kemp have been up to for the past 10 years. Edsinger co-founded Meka Robotics in 2007, which built expensive, high performance humanoid arms, torsos, and heads for the research market. Meka was notable for being the first robotics company (as far as we know) to sell robot arms that used series elastic actuators, and the company worked extensively with Georgia Tech researchers. In 2011, Edsinger was one of the co-founders of Redwood Robotics (along with folks from SRI and Willow Garage), which was going to develop some kind of secret and amazing new robot arm before Google swallowed it in late 2013. At the same time, Google also acquired Meka and a bunch of other robotics companies, and Edsinger ended up at Google as one of the directors of its robotics program, until he left to co-found Hello Robot in 2017.

Meanwhile, since 2007 Kemp has been a robotics professor at Georgia Tech, where he runs the Healthcare Robotics Lab. Kemp’s lab was one of the 11 PR2 beta sites, giving him early experience with a ginormous mobile manipulator. Much of the research that Kemp has spent the last decade on involves robots providing assistance to untrained users, often through direct physical contact, and frequently either in their own homes or in a home environment. We should mention that the Georgia Tech PR2 is still going, most recently doing some clever material classification work in a paper for IROS later this year.

Photo: Hello Robot

Hello Robot co-founder and CEO Aaron Edsinger says that, although Stretch is currently a research platform, he hopes to see the robot deployed in home environments, adding that the “impact we want to have is through robots that are helpful to people in society.”

So with all that in mind, where’d Hello Robot come from? As it turns out, both Edsinger and Kemp were in Rodney Brooks’ group at MIT, so it’s perhaps not surprising that they share some of the same philosophies about what robots should be and what they should be used for. After collaborating on a variety of projects over the years, in 2017 Edsinger was thinking about his next step after Google when Kemp stopped by to show off some video of a new robot prototype that he’d been working on—the prototype for Stretch. “As soon as I saw it, I knew that was exactly the kind of thing I wanted to be working on,” Edsinger told us. “I’d become frustrated with the complexity of the robots being built to do manipulation in home environments and around people, and it solved a lot of problems in an elegant way.”

For Kemp, Stretch is an attempt to get everything he’s been teaching his robots out of his lab at Georgia Tech and into the world where it can actually be helpful to people. “Right from the beginning, we were trying to take our robots out to real homes and interact with real people,” says Kemp. Georgia Tech’s PR2, for example, worked extensively with Henry and Jane Evans, helping Henry (a quadriplegic) regain some of the bodily autonomy he had lost. With the assistance of the PR2, Henry was able to keep himself comfortable for hours without needing a human caregiver to be constantly with him. “I felt like I was making a commitment in some ways to some of the people I was working with,” Kemp told us. “But 10 years later, I was like, where are these things? I found that incredibly frustrating. Stretch is an effort to try to push things forward.”

A robot you can put in the backseat of a car
One way to put Stretch in context is to think of it almost as a reaction to the kitchen sink philosophy of the PR2. Where the PR2 was designed to be all the robot anyone could ever need (plus plenty of robot that nobody really needed) embodied in a piece of hardware that weighs 225 kilograms and cost nearly half a million dollars, Stretch is completely focused on being just the robot that is actually necessary in a form factor that’s both much smaller and affordable. The entire robot weighs a mere 23 kg in a footprint that’s just a 34 cm square. As you can see from the video, it’s small enough (and safe enough) that it can be moved by a child. The cost? At $17,950 apiece—or a bit less if you buy a bunch at once—Stretch costs a fraction of what other mobile manipulators sell for.

It might not seem like size or weight should be that big of an issue, but it very much is, explains Maya Cakmak, a robotics professor at the University of Washington, in Seattle. Cakmak worked with PR2 and Henry Evans when she was at Willow Garage, and currently has access to both a PR2 and a Fetch research robot. “When I think about my long term research vision, I want to deploy service robots in real homes,” Cakmak told us. Unfortunately, it’s the robots themselves that have been preventing her from doing this—both the Fetch and the PR2 are large enough that moving them anywhere requires a truck and a lift, which also limits the home that they can be used in. “For me, I felt immediately that Stretch is very different, and it makes a lot of sense,” she says. “It’s safe and lightweight, you can probably put it in the backseat of a car.” For Cakmak, Stretch’s size is the difference between being able to easily take a robot to the places she wants to do research in, and not. And cost is a factor as well, since a cheaper robot means more access for her students. “I got my refurbished PR2 for $180,000,” Cakmak says. “For that, with Stretch I could have 10!”

“I felt immediately that Stretch is very different. It’s safe and lightweight, you can probably put it in the backseat of a car. I got my refurbished PR2 for $180,000. For that, with Stretch I could have 10!”
—Maya Cakmak, University of Washington

Of course, a portable robot doesn’t do you any good if the robot itself isn’t sophisticated enough to do what you need it to do. Stretch is certainly a compromise in functionality in the interest of small size and low cost, but it’s a compromise that’s been carefully thought out, based on the experience that Edsinger has building robots and the experience that Kemp has operating robots in homes. For example, most mobile manipulators are essentially multi-degrees-of-freedom arms on mobile bases. Stretch instead leverages its wheeled base to move its arm in the horizontal plane, which (most of the time) works just as well as an extra DoF or two on the arm while saving substantially on weight and cost. Similarly, Stretch relies almost entirely on one sensor, an Intel RealSense D435i on a pan-tilt head that gives it a huge range of motion. The RealSense serves as a navigation camera, manipulation camera, a 3D mapping system, and more. It’s not going to be quite as good for a task that might involve fine manipulation, but most of the time it’s totally workable and you’re saving on cost and complexity.

Stretch has been relentlessly optimized to be the absolutely minimum robot to do mobile manipulation in a home or workplace environment. In practice, this meant figuring out exactly what it was absolutely necessary for Stretch to be able to do. With an emphasis on manipulation, that meant defining the workspace of the robot, or what areas it’s able to usefully reach. “That was one thing we really had to push hard on,” says Edsinger. “Reachability.” He explains that reachability and a small mobile base tend not to go together, because robot arms (which tend to weigh a lot) can cause a small base to tip, especially if they’re moving while holding a payload. At the same time, Stretch needed to be able to access both countertops and the floor, while being able to reach out far enough to hand people things without having to be right next to them. To come up with something that could meet all those requirements, Edsinger and Kemp set out to reinvent the robot arm.

Stretch’s key innovation: a stretchable arm
The design they came up with is rather ingenious in its simplicity and how well it works. Edsinger explains that the arm consists of five telescoping links: one fixed and four moving. They are constructed of custom carbon fiber, and are driven by a single motor, which is attached to the robot’s vertical pole. The strong, lightweight structure allows the arm to extend over half a meter and hold up to 1.5 kg. Although the company has a patent pending for the design, Edsinger declined to say whether the links are driven by a belt, cables, or gears. “We don’t want to disclose too much of the secret sauce [with regard to] the drive mechanism.” He added that the arm was “one of the most significant engineering challenges on the robot in terms of getting the desired reach, compactness, precision, smoothness, force sensitivity, and low cost to all happily coexist.”

Photo: Hello Robot

Stretch’s arm consists of five telescoping links constructed of custom carbon fiber, and are driven by a single motor, which is attached to the robot’s vertical pole, minimizing weight and inertia. The arm has a reach of over half a meter and can hold up to 1.5 kg.

Another interesting features of Stretch is its interface with the world—its gripper. There are countless different gripper designs out there, each and every one of which is the best at gripping some particular subset of things. But making a generalized gripper for all of the stuff that you’d find in a home is exceptionally difficult. Ideally, you’d want some sort of massive experimental test program where thousands and thousands of people test out different gripper designs in their homes for long periods of time and then tell you which ones work best. Obviously, that’s impractical for a robotics startup, but Kemp realized that someone else was already running the study for him: Amazon.

“I had this idea that there are these assistive grabbers that people with disabilities use to grasp objects in the real world,” he told us. Kemp went on Amazon’s website and looked at the top 10 grabbers and the reviews from thousands of users. He then bought a bunch of different ones and started testing them. “This one [Stretch’s gripper], I almost didn’t order it, it was such a weird looking thing,” he says. “But it had great reviews on Amazon, and oh my gosh, it just blew away the other grabbers. And I was like, that’s it. It just works.”

Stretch’s teleoperated and autonomous capabilities
As with any robot intended to be useful outside of a structured environment, hardware is only part of the story, and arguably not even the most important part. In order for Stretch to be able to operate out from under the supervision of a skilled roboticist, it has to be either easy to control, or autonomous. Ideally, it’s both, and that’s what Hello Robot is working towards, although things didn’t start out that way, Kemp explains. “From a minimalist standpoint, we began with the notion that this would be a teleoperated robot. But in the end, you just don’t get the real power of the robot that way, because you’re tied to a person doing stuff. As much as we fought it, autonomy really is a big part of the future for this kind of system.”

Here’s a look at some of Stretch’s teleoperated capabilities. We’re told that Stretch is very easy to get going right out of the box, although this teleoperation video from Hello Robot looks like it’s got a skilled and experienced user in the loop:

For such a low-cost platform, the autonomy (even at this early stage) is particularly impressive:

Since it’s not entirely clear from the video exactly what’s autonomous, here’s a brief summary of a couple of the more complex behaviors that Kemp sent us:

Object grasping: Stretch uses its 3D camera to find the nearest flat surface using a virtual overhead view. It then segments significant blobs on top of the surface. It selects the largest blob in this virtual overhead view and fits an ellipse to it. It then generates a grasp plan that makes use of the center of the ellipse and the major and minor axes. Once it has a plan, Stretch orients its gripper, moves to the pre-grasp pose, moves to the grasp pose, closes its gripper based on the estimated object width, lifts up, and retracts.
Mapping, navigating, and reaching to a 3D point: These demonstrations all use FUNMAP (Fast Unified Navigation, Manipulation and Planning). It’s all novel custom Python code. Even a single head scan performed by panning the 3D camera around can result in a very nice 3D representation of Stretch’s surroundings that includes the nearby floor. This is surprisingly unusual for robots, which often have their cameras too low to see many interesting things in a human environment. While mapping, Stretch selects where to scan next in a non-trivial way that considers factors such as the quality of previous observations, expected new observations, and navigation distance. The plan that Stretch uses to reach the target 3D point has been optimized for navigation and manipulation. For example, it finds a final robot pose that provides a large manipulation workspace for Stretch, which must consider nearby obstacles, including obstacles on the ground.
Object handover: This is a simple demonstration of object handovers. Stretch performs Cartesian motions to move its gripper to a body-relative position using a good motion heuristic, which is to extend the arm as the last step. These simple motions work well due to the design of Stretch. It still surprises me how well it moves the object to comfortable places near my body, and how unobtrusive it is. The goal point is specified relative to a 3D frame attached to the person’s mouth estimated using deep learning models (shown in the RViz visualization video). Specifically, Stretch targets handoff at a 3D point that is 20 cm below the estimated position of the mouth and 25 cm away along the direction of reaching.

Much of these autonomous capabilities come directly from Kemp’s lab, and the demo code is available for anyone to use. (Hello Robot says all of Stretch’s software is open source.)

Photo: Hello Robot

Hello Robot co-founder and CEO Aaron Edsinger says Stretch is designed to work with people in homes and workplaces and can be teleoperated to do a variety of tasks, including picking up toys, removing laundry from a dryer, and playing games with kids.

As of right now, Stretch is very much a research platform. You’re going to see it in research labs doing research things, and hopefully in homes and commercial spaces as well, but still under the supervision of professional roboticists. As you may have guessed, though, Hello Robot’s vision is a bit broader than that. “The impact we want to have is through robots that are helpful to people in society,” Edsinger says. “We think primarily in the home context, but it could be in healthcare, or in other places. But we really want to have our robots be impactful, and useful. To us, useful is exciting.” Adds Kemp: “I have a personal bias, but we’d really like this technology to benefit older adults and caregivers. Rather than creating a specialized assistive device, we want to eventually create an inexpensive consumer device for everyone that does lots of things.”

Neither Edsinger nor Kemp would say much more on this for now, and they were very explicit about why—they’re being deliberately cautious about raising expectations, having seen what’s happened to some other robotics companies over the past few years. Without VC funding (Hello Robot is currently bootstrapping itself into existence), Stretch is being sold entirely on its own merits. So far, it seems to be working. Stretch robots are already in a half dozen research labs, and we expect that with today’s announcement, we’ll start seeing them much more frequently.

This article appears in the October 2020 print issue as “A Robot That Keeps It Simple.” Continue reading

Posted in Human Robots

#437709 iRobot Announces Major Software Update, ...

Since the release of the very first Roomba in 2002, iRobot’s long-term goal has been to deliver cleaner floors in a way that’s effortless and invisible. Which sounds pretty great, right? And arguably, iRobot has managed to do exactly this, with its most recent generation of robot vacuums that make their own maps and empty their own dustbins. For those of us who trust our robots, this is awesome, but iRobot has gradually been realizing that many Roomba users either don’t want this level of autonomy, or aren’t ready for it.

Today, iRobot is announcing a major new update to its app that represents a significant shift of its overall approach to home robot autonomy. Humans are being brought back into the loop through software that tries to learn when, where, and how you clean so that your Roomba can adapt itself to your life rather than the other way around.

To understand why this is such a shift for iRobot, let’s take a very brief look back at how the Roomba interface has evolved over the last couple of decades. The first generation of Roomba had three buttons on it that allowed (or required) the user to select whether the room being vacuumed was small or medium or large in size. iRobot ditched that system one generation later, replacing the room size buttons with one single “clean” button. Programmable scheduling meant that users no longer needed to push any buttons at all, and with Roombas able to find their way back to their docking stations, all you needed to do was empty the dustbin. And with the most recent few generations (the S and i series), the dustbin emptying is also done for you, reducing direct interaction with the robot to once a month or less.

Image: iRobot

iRobot CEO Colin Angle believes that working toward more intelligent human-robot collaboration is “the brave new frontier” of AI. “This whole journey has been earning the right to take this next step, because a robot can’t be responsive if it’s incompetent,” he says. “But thinking that autonomy was the destination was where I was just completely wrong.”

The point that the top-end Roombas are at now reflects a goal that iRobot has been working toward since 2002: With autonomy, scheduling, and the clean base to empty the bin, you can set up your Roomba to vacuum when you’re not home, giving you cleaner floors every single day without you even being aware that the Roomba is hard at work while you’re out. It’s not just hands-off, it’s brain-off. No noise, no fuss, just things being cleaner thanks to the efforts of a robot that does its best to be invisible to you. Personally, I’ve been completely sold on this idea for home robots, and iRobot CEO Colin Angle was as well.

“I probably told you that the perfect Roomba is the Roomba that you never see, you never touch, you just come home everyday and it’s done the right thing,” Angle told us. “But customers don’t want that—they want to be able to control what the robot does. We started to hear this a couple years ago, and it took a while before it sunk in, but it made sense.”

How? Angle compares it to having a human come into your house to clean, but you weren’t allowed to tell them where or when to do their job. Maybe after a while, you’ll build up the amount of trust necessary for that to work, but in the short term, it would likely be frustrating. And people get frustrated with their Roombas for this reason. “The desire to have more control over what the robot does kept coming up, and for me, it required a pretty big shift in my view of what intelligence we were trying to build. Autonomy is not intelligence. We need to do something more.”

That something more, Angle says, is a partnership as opposed to autonomy. It’s an acknowledgement that not everyone has the same level of trust in robots as the people who build them. It’s an understanding that people want to have a feeling of control over their homes, that they have set up the way that they want, and that they’ve been cleaning the way that they want, and a robot shouldn’t just come in and do its own thing.

This change in direction also represents a substantial shift in resources for iRobot, and the company has pivoted two-thirds of its engineering organization to focus on software-based collaborative intelligence rather than hardware.

“Until the robot proves that it knows enough about your home and about the way that you want your home cleaned,” Angle says, “you can’t move forward.” He adds that this is one of those things that seem obvious in retrospect, but even if they’d wanted to address the issue before, they didn’t have the technology to solve the problem. Now they do. “This whole journey has been earning the right to take this next step, because a robot can’t be responsive if it’s incompetent,” Angle says. “But thinking that autonomy was the destination was where I was just completely wrong.”

The previous iteration of the iRobot app (and Roombas themselves) are built around one big fat CLEAN button. The new approach instead tries to figure out in much more detail where the robot should clean, and when, using a mixture of autonomous technology and interaction with the user.

Where to Clean
Knowing where to clean depends on your Roomba having a detailed and accurate map of its environment. For several generations now, Roombas have been using visual mapping and localization (VSLAM) to build persistent maps of your home. These maps have been used to tell the Roomba to clean in specific rooms, but that’s about it. With the new update, Roombas with cameras will be able to recognize some objects and features in your home, including chairs, tables, couches, and even countertops. The robots will use these features to identify where messes tend to happen so that they can focus on those areas—like around the dining room table or along the front of the couch.

We should take a minute here to clarify how the Roomba is using its camera. The original (primary?) purpose of the camera was for VSLAM, where the robot would take photos of your home, downsample them into QR-code-like patterns of light and dark, and then use those (with the assistance of other sensors) to navigate. Now the camera is also being used to take pictures of other stuff around your house to make that map more useful.

Photo: iRobot

The robots will now try to fit into the kinds of cleaning routines that many people already have established. For example, the app may suggest an “after dinner” routine that cleans just around the kitchen and dining room table.

This is done through machine learning using a library of images of common household objects from a floor perspective that iRobot had to develop from scratch. Angle clarified for us that this is all done via a neural net that runs on the robot, and that “no recognizable images are ever stored on the robot or kept, and no images ever leave the robot.” Worst case, if all the data iRobot has about your home gets somehow stolen, the hacker would only know that (for example) your dining room has a table in it and the approximate size and location of that table, because the map iRobot has of your place only stores symbolic representations rather than images.

Another useful new feature is intended to help manage the “evil Roomba places” (as Angle puts it) that every home has that cause Roombas to get stuck. If the place is evil enough that Roomba has to call you for help because it gave up completely, Roomba will now remember, and suggest that either you make some changes or that it stops cleaning there, which seems reasonable.

When to Clean
It turns out that the primary cause of mission failure for Roombas is not that they get stuck or that they run out of battery—it’s user cancellation, usually because the robot is getting in the way or being noisy when you don’t want it to be. “If you kill a Roomba’s job because it annoys you,” points out Angle, “how is that robot being a good partner? I think it’s an epic fail.” Of course, it’s not the robot’s fault, because Roombas only clean when we tell them to, which Angle says is part of the problem. “People actually aren’t very good at making their own schedules—they tend to oversimplify, and not think through what their schedules are actually about, which leads to lots of [figurative] Roomba death.”

To help you figure out when the robot should actually be cleaning, the new app will look for patterns in when you ask the robot to clean, and then recommend a schedule based on those patterns. That might mean the robot cleans different areas at different times every day of the week. The app will also make scheduling recommendations that are event-based as well, integrated with other smart home devices. Would you prefer the Roomba to clean every time you leave the house? The app can integrate with your security system (or garage door, or any number of other things) and take care of that for you.

More generally, Roomba will now try to fit into the kinds of cleaning routines that many people already have established. For example, the app may suggest an “after dinner” routine that cleans just around the kitchen and dining room table. The app will also, to some extent, pay attention to the environment and season. It might suggest increasing your vacuuming frequency if pollen counts are especially high, or if it’s pet shedding season and you have a dog. Unfortunately, Roomba isn’t (yet?) capable of recognizing dogs on its own, so the app has to cheat a little bit by asking you some basic questions.

A Smarter App

Image: iRobot

The previous iteration of the iRobot app (and Roombas themselves) are built around one big fat CLEAN button. The new approach instead tries to figure out in much more detail where the robot should clean, and when, using a mixture of autonomous technology and interaction with the user.

The app update, which should be available starting today, is free. The scheduling and recommendations will work on every Roomba model, although for object recognition and anything related to mapping, you’ll need one of the more recent and fancier models with a camera. Future app updates will happen on a more aggressive schedule. Major app releases should happen every six months, with incremental updates happening even more frequently than that.

Angle also told us that overall, this change in direction also represents a substantial shift in resources for iRobot, and the company has pivoted two-thirds of its engineering organization to focus on software-based collaborative intelligence rather than hardware. “It’s not like we’re done doing hardware,” Angle assured us. “But we do think about hardware differently. We view our robots as platforms that have longer life cycles, and each platform will be able to support multiple generations of software. We’ve kind of decoupled robot intelligence from hardware, and that’s a change.”

Angle believes that working toward more intelligent collaboration between humans and robots is “the brave new frontier of artificial intelligence. I expect it to be the frontier for a reasonable amount of time to come,” he adds. “We have a lot of work to do to create the type of easy-to-use experience that consumer robots need.” Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots